A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
NCT ID: NCT03232593
Last Updated: 2022-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1758 participants
OBSERVATIONAL
2017-11-29
2022-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
NCT03399643
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
NCT02589717
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
NCT03835949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants who Receive Atezolizumab
Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
Atezolizumab
Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongnam Inst.of Radiological & Medical Sciences
Busan, , South Korea
Inje University Busan Paik Hospital
Busan, , South Korea
Inje university Haeundae Paik Hospital
Busan, , South Korea
Dong-A University Hospital
Busan, , South Korea
Pusan National University Hospital
Busan, , South Korea
Kosin University Gospel Hospital
Busan, , South Korea
Donga Uni Medical Center; Pulmonary
Busan, , South Korea
Pusan University Hospital
Busan, , South Korea
Pusan University Hospital; Hemato-oncology
Busan, , South Korea
Kyungpook National University Medical Center
Daegu, , South Korea
Keimyung University Dongsan Medical Center
Daegu, , South Korea
Daegu Catholic University Medical Center
Daegu, , South Korea
Keimyung University Dongsan Hospital; Pulmonology
Daegu, , South Korea
Konyang University Hospital
Daejeon, , South Korea
Hallym University Medical Center Chuncheon Sacred Heart Hospital
Gangwon-do, , South Korea
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, , South Korea
Gangneung Asan Hospital
Gangwon-do, , South Korea
Uijeongbu St. Mary's Hospital
Gyeonggi-do, , South Korea
CHA Bundang Medical Center
Gyeonggi-do, , South Korea
Hallym University Sacred Heart Hospital
Gyeonggi-do, , South Korea
Soonchunhyang University Bucheon Hospital
Gyeonggi-do, , South Korea
Bucheon St Mary's hospital
Gyeonggi-do, , South Korea
Korea University Ansan Hospital
Gyeonggi-do, , South Korea
St. Vincent's Hospital
Gyeonggi-do, , South Korea
Pusan National University Yangsan Hospital
Gyeongsangnam-do, , South Korea
Hallym University Dongtan Sacred Heart Hospital
Hwaseong-si, , South Korea
Chonbuk National University Hospital
Jeollabuk-do, , South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, , South Korea
Wonkwang University School of Medicine & Hospital
Jeonlabuk-do, , South Korea
Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Eunpyeong St. Mary's Hoapital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Severance Hospital, Yonsei University
Seoul, , South Korea
Soonchunhyang University Hospital
Seoul, , South Korea
Hanyang University Medical Center
Seoul, , South Korea
Gangdong Kyung Hee University Hospital
Seoul, , South Korea
VHS Medical Center
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul St Mary's Hospital
Seoul, , South Korea
ChungAng University Hospital
Seoul, , South Korea
Borame Medical Center
Seoul, , South Korea
Yeouido St. Mary's Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System; Oncology
Seoul, , South Korea
Samsung Medical Centre; Division of Hematology/Oncology
Seoul, , South Korea
Ewha Womans University Mokdong Hospital; Urology
Seoul, , South Korea
Korea Uni Anam Hospital; Internal Medicine
Seoul, , South Korea
SoonChunHyang University Hospital Seoul
Seoul, , South Korea
Ulsan University Hosiptal
Ulsan, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Yonsei University Wonju Severance Christian Hospital
Wŏnju, , South Korea
Pusan National University Yangsan Hospital; hemato-oncology
Yangsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML39313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.